Drugs Made In America Acquisition II Corp. Unit
Limited financial coverage for DMIIU.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing.
- CEO
- Roger Bendelac
- IPO
- 2025
- Employees
- 2
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DMIIU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $10.80
- 52W Low
- $9.96
- 50D MA
- $10.19
- 200D MA
- $10.11
- Beta
- 0.06
- RSI (14)
- 49
- Avg Volume
- 389
No earnings-call transcripts are available for DMIIU yet.
- Free Float
- 72.3%
- Shares Outstanding
- 69.54M
- Float Shares
- 50.26M
Our DMIIU coverage
Recent articles, reports, and earnings notes.
No research on DMIIU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMIIU report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.